SARS-CoV-2 nucleocapsid phosphoprotein

RefSeq NC_045512

Also Known As:

nucleocapsid phosphoprotein, SARS-CoV-2; N protein, SARS-CoV-2; N protein, severe acute respiratory syndrome coronavirus 2; nucleocapsid phosphoprotein, 2019 novel coronavirus; nucleocapsid phosphoprotein, 2019-nCoV; nucleocapsid phosphoprotein, COVID-19 virus; nucleocapsid phosphoprotein, COVID19 virus; nucleocapsid phosphoprotein, severe acute respiratory syndrome coronavirus 2; nucleocapsid protein, 2019 novel coronavirus; nucleocapsid protein, 2019-nCoV; nucleocapsid protein, COVID-19 virus; nucleocapsid protein, COVID19 virus; nucleocapsid protein, SARS-CoV-2; nucleocapsid protein, severe acute respiratory syndrome coronavirus 2; nucleoprotein, SARS-CoV-2; orf9 protein, SARS-CoV-2

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Viral Proteins: 4250
    - Viral Structural Proteins: 171
      - Nucleocapsid Proteins: 749
        Coronavirus Nucleocapsid Proteins: 8
        SARS-CoV-2 nucleocapsid phosphoprotein: 3
  - Phosphoproteins: 1772
    - SARS-CoV-2 nucleocapsid phosphoprotein: 3

Experts

1.	Araújo-Santos, Théo: 1 article (01/2022)
2.	Baranwal, Manoj: 1 article (01/2022)
3.	Barbosa, Larissa Gomes: 1 article (01/2022)
4.	Davidyuk, Yuriy: 1 article (01/2022)
5.	Foster, Toshana L: 1 article (01/2022)
6.	Garanina, Ekaterina: 1 article (01/2022)
7.	Gonzaga Knnup, Lívia Vasconcelos: 1 article (01/2022)
8.	Hamza, Shaimaa: 1 article (01/2022)
9.	Kaushal, Neha: 1 article (01/2022)
10.	Khaiboullina, Svetlana: 1 article (01/2022)

Related Diseases

1.	COVID-19 01/01/2022 - "To compare the fitness of 2 primer sets to the SARS-CoV-2 nucleocapsid phosphoprotein gene (NP) in the molecular diagnosis of COVID-19, we verified the inconclusive data and confidence of high cycle threshold (Ct) values in SARS-CoV-2 detection. " 01/01/2022 - "Here, we analyzed and quantified the reactivity of serum samples from acute (non-fatal and fatal) and convalescent COVID-19 patients with the spike surface glycoprotein (S protein) and nucleocapsid phosphoprotein (N protein) SARS-CoV-2 peptide libraries. " 12/01/2020 - "Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays. "
2.	Syphilis 12/01/2020 - "Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays. "
3.	Infections 12/01/2020 - "Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays. "
4.	Body Weight (Weight, Body) 12/01/2020 - "Mild/moderate COVID-19 convalescents were selected as CCP donors after reverse transcription polymerase chain reaction (RT-PCR) confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and absence of symptoms for ≥14 days plus (a) age (18-60 years), body weight greater than 55 kg; (b) immunohematological studies; (c) no infectious markers of hepatitis B virus, hepatitis C virus, human immunodeficiency virus, human T-lymphotropic virus-1/2, Chagas and syphilis infection; (d) no HLA antibodies (multiparous); (e) second RT-PCR (nasopharyngeal swab and/or blood) negativity; (f) virus neutralization test (cytopathic effect-based virus neutralization test neutralizing antibody) and anti-nucleocapsid protein SARS-CoV-2 IgM, IgG, and IgA enzyme-linked immunosorbent assays. "

Related Drugs and Biologics

1.	Neutralizing Antibodies
2.	Immunosorbents
3.	Immunoglobulin M (IgM)
4.	Immunoglobulin G (IgG)
5.	Immunoglobulin A (IgA)
6.	Enzymes
7.	Antibodies
8.	Peptide Library
9.	Proteins (Proteins, Gene)
10.	Phosphoproteins